Olema Oncology reports early phase 1 data for cancer drug OP-3136

May 21, 2026 5:00 PM

Olema Oncology (NASDAQ: OLMA) announced preliminary results from its phase 1 study of OP-3136, an experimental cancer treatment targeting the ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

No results found